BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 8202048)

  • 1. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report.
    Heyn R; Khan F; Ensign LG; Donaldson SS; Ruymann F; Smith MA; Vietti T; Maurer HM
    Med Pediatr Oncol; 1994; 23(2):99-106. PubMed ID: 8202048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double recurrence of double cancers: Rhabdomyosarcoma and secondary AML.
    Kajita N; Saito Y; Makimoto A; Miyahara S; Yuza Y
    Pediatr Int; 2020 Jun; 62(6):742-744. PubMed ID: 32495974
    [No Abstract]   [Full Text] [Related]  

  • 3. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.
    Kollmannsberger C; Beyer J; Droz JP; Harstrick A; Hartmann JT; Biron P; Fléchon A; Schöffski P; Kuczyk M; Schmoll HJ; Kanz L; Bokemeyer C
    J Clin Oncol; 1998 Oct; 16(10):3386-91. PubMed ID: 9779717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma.
    Sugita K; Furukawa T; Tsuchida M; Okawa Y; Nakazawa S; Akatsuka J; Ohira M; Nishimura K
    Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):99-104. PubMed ID: 8447565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A report on second neo-plasms in seven children with solid tumors.
    Hu H; Zhang W; Li J; Li F; Li R; Liu Z; Huang D
    Ann Ital Chir; 2022; 92():331-338. PubMed ID: 36052474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary leukemia in a child conceived using in vitro fertilization.
    Kim YD; Kim KJ; Lee YH
    Pediatr Int; 2008 Dec; 50(6):831-2. PubMed ID: 19067904
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute myelogenous leukemia after treatment for malignant germ cell tumors in children.
    Schneider DT; Hilgenfeld E; Schwabe D; Behnisch W; Zoubek A; Wessalowski R; Göbel U
    J Clin Oncol; 1999 Oct; 17(10):3226-33. PubMed ID: 10506623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer.
    Yagita M; Ieki Y; Onishi R; Huang CL; Adachi M; Horiike S; Konaka Y; Taki T; Miyake M
    Int J Oncol; 1998 Jul; 13(1):91-6. PubMed ID: 9625808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
    Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
    Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.
    Eichenauer DA; Thielen I; Haverkamp H; Franklin J; Behringer K; Halbsguth T; Klimm B; Diehl V; Sasse S; Rothe A; Fuchs M; Böll B; von Tresckow B; Borchmann P; Engert A
    Blood; 2014 Mar; 123(11):1658-64. PubMed ID: 24478403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols.
    Nichols CR; Breeden ES; Loehrer PJ; Williams SD; Einhorn LH
    J Natl Cancer Inst; 1993 Jan; 85(1):36-40. PubMed ID: 7677934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood.
    Douglas JG; Arndt CA; Hawkins DS
    Eur J Cancer; 2007 Apr; 43(6):1045-50. PubMed ID: 17368885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.
    Kushner BH; Heller G; Cheung NK; Wollner N; Kramer K; Bajorin D; Polyak T; Meyers PA
    J Clin Oncol; 1998 Sep; 16(9):3016-20. PubMed ID: 9738570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients.
    Inoue Y; Nakamura T; Nakanishi H; Oishi M; Hongo F; Okihara K; Mizutani S; Kuroda J; Ukimura O
    Int J Urol; 2018 Jul; 25(7):678-683. PubMed ID: 29752743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
    Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
    Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study.
    Arndt C; Tefft M; Gehan E; Anderson J; Jenson M; Link M; Donaldson S; Breneman J; Wiener E; Webber B; Maurer H
    J Pediatr Hematol Oncol; 1997; 19(2):124-9. PubMed ID: 9149741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks.
    Smith MA; Rubinstein L; Ungerleider RS
    Med Pediatr Oncol; 1994; 23(2):86-98. PubMed ID: 8202047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Third Intergroup Rhabdomyosarcoma Study.
    Crist W; Gehan EA; Ragab AH; Dickman PS; Donaldson SS; Fryer C; Hammond D; Hays DM; Herrmann J; Heyn R
    J Clin Oncol; 1995 Mar; 13(3):610-30. PubMed ID: 7884423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
    J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.